GHRP-6: what the research shows

  • By Reed Calder
  • Last reviewed Nov 12, 2026
  • 28 studies and official documents checked

In short

GHRP-6 is a lab-made six-amino-acid peptide, the first of the growth hormone releasing peptides, that copies the signal of the hormone ghrelin. An intravenous dose gave a large, short surge of growth hormone in healthy men, and paired with growth-hormone-releasing hormone it is used as a test for growth hormone deficiency. It also raised cortisol and ACTH, and in men it added about 25 minutes of stage 2 sleep. It is widely said to cause intense hunger, but we found no trial of GHRP-6 that measured appetite: that claim comes from ghrelin and from a related peptide. The one large trial, in stroke patients and combined with EGF, missed its main goal. GHRP-6 isn’t approved anywhere we found, and the World Anti-Doping Agency bans it at all times.

EvidenceCellAnimalHuman

GHRP-6 is sold online as a “peptide” for appetite, muscle, recovery and anti-aging. This page covers what it is, what the human studies found by injection and by mouth, the sleep and hormone effects, its use as a diagnostic test, the stroke trial, the animal work, and where it stands legally.

Names and forms you’ll see

The names on GHRP-6 products
Name What it is Studied in people?
GHRP-6 Growth hormone-releasing peptide 6, a lab-made peptide of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) (Cabrales et al., 2013) Yes
Hexapeptide-2 The name the FDA’s substance registry uses for GHRP-6 (FDA GSRS) Same as GHRP-6
GHRP-6 acetate The salt form often sold as a powder, with a registry record of its own (FDA GSRS). The studies we read don’t say which form was used Unclear
[D-Lys3]-GHRP-6 A different compound: a lab tool that blocks the ghrelin receptor (Zhang et al., 2023). It is not what is sold as GHRP-6 Rarely
“GHRP-6 peptide” A search phrase and a sales label for the same compound Same as GHRP-6

CAS numbers

A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The base and the acetate salt have different registry numbers.

GHRP-6 CAS numbers
Form CAS number Registry record
GHRP-6 (Hexapeptide-2), free base 87616-84-0 FDA GSRS
GHRP-6 acetate (Hexapeptide-2 acetate) 145177-42-0 FDA GSRS

What GHRP-6 is

The growth hormone releasing peptides were found by the endocrinologist Cyril Bowers, who saw that chemical relatives of an enkephalin peptide made pituitary cells release growth hormone (GH). GHRP-6 was the first of them (Berlanga-Acosta et al., 2017). It binds the same receptor as ghrelin, a hormone made mostly in the stomach, so it acts as a ghrelin mimic. A review also describes a second receptor, CD36, for the group (Berlanga-Acosta et al., 2017).

It still needs the body’s own growth-hormone-releasing hormone (GHRH). In nine healthy men, a GHRH blocker cut the maximal GH rise after GHRP-6 from 33.8 to 6.2 micrograms per litre (Pandya et al., 1998).

In nine healthy men given single intravenous injections of 100, 200 and 400 micrograms per kilogram, GHRP-6 left the blood in two phases, with half-lives of 7.6 minutes and 2.5 hours. Blood levels rose in proportion to dose, and four of the nine men had unexplained spikes during elimination (Cabrales et al., 2013). Those doses are 100 to 400 times the ones used in the diagnostic tests below.

Hexarelin was derived from GHRP-6; see hexarelin. Other compounds in this group are ipamorelin, GHRP-2 and the non-peptide MK-677.

What has been studied

Growth hormone release in people

  • By injection versus by mouth. In 10 normal men given placebo, oral doses of 30, 100 and 300 micrograms per kilogram, and an intravenous 1 microgram per kilogram, one week apart, peak GH was 4.0, 5.2, 9.2, 18 and 26 micrograms per litre. Only the 300 microgram dose beat placebo, and it matched the intravenous dose. The injection worked faster (Hartman et al., 1992).
  • Children. In 13 children aged 6 to 10 with normal short stature, 300 micrograms per kilogram by mouth raised GH to a peak of 18.8 micrograms per litre from 1.1 at baseline in the first 7, much like an injection of growth-hormone-releasing hormone (20.8 from 2.2) (Bellone et al., 1995).
  • Older women, 4 days. Seven women aged 65 to 82 took 300 micrograms per kilogram by mouth twice a day for 4 days. Their GH response was kept (peak 10.7 before, 16.8 after), and IGF-1 did not rise significantly (77.1 vs 84.1 micrograms per litre) (Ghigo et al., 1994).
  • Other routes, overnight. In young men, 300 micrograms per kilogram in enteric-coated capsules at 9 pm left GH, ACTH and cortisol unchanged. A nasal spray of 30 micrograms per kilogram at 10:45 pm raised GH across the night, and a sublingual dose of the same size showed only a trend (Frieboes et al., 1999).

Use as a diagnostic test

  • With GHRH. In 125 adults with pituitary disease and 125 healthy adults, 1 microgram per kilogram each of GHRH and GHRP-6 by vein gave a mean GH peak of 59.2 micrograms per litre in controls and 4.1 in patients, a bigger gap than the standard insulin tolerance test (14.3 and 0.5). No side effects were reported, and age, sex and body fat did not change the result (Popovic et al., 2000).
  • Alone. In 49 patients and 20 controls, GHRP-6 at 1 microgram per kilogram identified adult GH deficiency with 80% sensitivity and 95% specificity at a cut-off of 3.5 micrograms per litre. No side effects were seen (Alaioubi et al., 2009).
  • For the adrenal glands. The same dose raised cortisol, and its peak was 227 nmol/L in people with adrenal insufficiency and 395 in people without. As a test it was less accurate than the insulin tolerance test (71% sensitivity, 78% specificity) (Alaioubi et al., 2010).

Cortisol and sleep

  • Four injections overnight. In normal men, four intravenous doses of 50 micrograms through the night raised GH (15.4 vs 5.5 ng/mL on placebo), ACTH (21.0 vs 16.6 pg/mL) and cortisol (56.0 vs 25.2 ng/mL). Stage 2 sleep rose by about 25 minutes (270 vs 245), and deep, slow-wave sleep did not change (Frieboes et al., 1995). Hexarelin, a relative, cut deep sleep in a similar design (Frieboes et al., 2004).

Appetite

  • No GHRP-6 trial. We found no human trial of GHRP-6 that measured hunger or food intake. A 2026 review calls an appetite response “characteristic” of GHRP-6, but its references there are a review of ghrelin and a review of secretagogues in hypogonadal men (Dominikowski et al., 2026).
  • A relative. GHRP-2, infused at 1 microgram per kilogram an hour for 270 minutes in 7 lean men, raised what they ate at a buffet by 35.9% (Laferrère et al., 2005).

Stroke, with EGF

  • COURAGE-2. This open-label phase 3 trial gave 188 adults within 12 hours of an ischaemic stroke either standard care or intravenous EGF (75 micrograms) with GHRP-6 (5 mg) twice a day for 7 days. It missed its primary goal: disability, survival and daily function did not differ overall. Severe adverse events were more common on treatment (30 of 95 vs 18 of 93; odds ratio 1.92, 95% CI 0.98 to 3.77), and none were judged treatment-related. In 27 people with severe strokes (NIHSS 15 or more), disability and deaths were lower on treatment, a subgroup finding outside the main analysis. Some authors work for the developer, which declares it (Hernández-Bernal et al., 2026).

Animals

  • Heart attack in pigs. With a coronary artery blocked for an hour, pigs given 400 micrograms per kilogram had 78% less dead heart tissue by mass after 72 hours than pigs given saline (Berlanga et al., 2007).
  • Organ injury in rats and gerbils. In rats, 120 micrograms per kilogram into the abdomen cut liver, gut, lung and kidney injury after a blood-flow blockage, by 50 to 85% in the liver and gut, and EGF added to the benefit (Cibrián et al., 2006). In gerbils after a brief stop in brain blood flow, EGF (100 micrograms per kilogram) with GHRP-6 (600) within 4 hours improved survival and shrank the damaged area (Subirós et al., 2016).
  • Who wrote it. These studies, the 2017 review of the evidence (Berlanga-Acosta et al., 2017) and the pharmacokinetic paper come from the Center for Genetic Engineering and Biotechnology in Havana, which is also behind the stroke trial, so they are not independent.

EvidenceCellAnimalHuman

The usual claims, checked

Common GHRP-6 claims vs the studies
Claim Verdict What the studies found
It causes intense hunger Untested We found no trial of GHRP-6 that measured appetite (Dominikowski et al., 2026). GHRP-2 raised buffet intake by 35.9% in 7 men (Laferrère et al., 2005)
It boosts growth hormone a lot Supported True for a single intravenous dose: a peak of 26 micrograms per litre against 4.0 on placebo (Hartman et al., 1992). It depends on the body’s own GHRH (Pandya et al., 1998)
It works by mouth Mixed Only at 300 micrograms per kilogram; 30 and 100 did not beat placebo (Hartman et al., 1992). Capsules at that dose did nothing overnight (Frieboes et al., 1999)
It builds muscle or raises IGF-1 Untested IGF-1 did not rise significantly after 4 days of oral dosing in older women (Ghigo et al., 1994). A 2026 review says body-composition evidence for this group is limited (Dominikowski et al., 2026)
It heals joints, gut and heart Untested The results are from pigs, rats and gerbils, mostly from the developer’s own group (Berlanga et al., 2007; Cibrián et al., 2006). The one large human trial, in stroke, missed its main goal (Hernández-Bernal et al., 2026)
It improves sleep Mixed Four injections overnight added about 25 minutes of stage 2 sleep and left deep sleep unchanged, while raising cortisol (Frieboes et al., 1995). Other routes showed trends at most (Frieboes et al., 1999)
It has no side effects Contradicted None were reported in one-dose diagnostic tests (Popovic et al., 2000). It raised cortisol and ACTH (Frieboes et al., 1995), and we found no multi-week trial of GHRP-6 alone
It is better than GHRP-2, hexarelin or ipamorelin Untested We found no human trial that compared them. See hexarelin and ipamorelin for what each shows
It is the same as D-Lys3-GHRP-6 Contradicted No. That compound blocks the ghrelin receptor (Zhang et al., 2023)

Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.

Side effects and safety

  • Hormones. Cortisol and ACTH rose after injections (Frieboes et al., 1995), and cortisol rise is the basis of a test for adrenal function (Alaioubi et al., 2010).
  • What the FDA says. It lists GHRP-6 among bulk substances that raise safety concerns for outsourcing facilities, citing the risk of immune reactions from clumping and impurities, an effect on cortisol, and a blood sugar rise from lower insulin sensitivity. It says it has identified limited safety information (FDA, 2026).
  • Stroke trial. Severe adverse events were more common on treatment (30 of 95 vs 18 of 93), though none were judged treatment-related and the difference was not statistically significant (Hernández-Bernal et al., 2026).
  • Blood levels. Four of nine men given very large intravenous doses had unexplained concentration spikes (Cabrales et al., 2013).
  • Short studies. The tests lasted one day, the oral courses 4 days and the stroke trial 7 days. We found nothing longer for GHRP-6 alone.
  • What is in the vial. A lab analysis of black-market growth products found versions of GHRP-6, GHRP-2 and ipamorelin with an extra glycine added at the front (Krug et al., 2018).

Legal and approval status

  • No approved product. Drugs@FDA lists no GHRP-6 product (openFDA search, no match), and ClinicalTrials.gov lists no study under the name (ClinicalTrials.gov search).
  • On the FDA’s compounding lists. GHRP-6 is on the FDA’s safety-risk page for outsourcing facilities, dated September 2023 (FDA, 2026), and in category 3 of its May 2026 compounding categories, nominated without adequate support (FDA list, May 2026).
  • Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
  • Banned in sport at all times. The World Anti-Doping Agency’s 2026 list names GHRP-6 under S2, prohibited in and out of competition (WADA, 2026).
  • “Research use only” products aren’t approved for use in people.

What to look for if you research it

We don’t name or link sellers. These checks come from the studies and registries:

  • Which form? The base is CAS 87616-84-0 and the acetate is 145177-42-0 (FDA GSRS; FDA GSRS).
  • What is actually in it. Black-market products have been found with glycine-extended versions (Krug et al., 2018). A lab report should confirm the exact sequence.
  • Antagonist or agonist. [D-Lys3]-GHRP-6 blocks the receptor that GHRP-6 activates (Zhang et al., 2023).
  • Hunger claims. A page promising “intense hunger” or “bulking” should say which trial measured it. We found none for GHRP-6.

Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other compounds in this group, see growth hormone secretagogues.

What’s still unknown

  • Whether GHRP-6 raises hunger or food intake in people, measured in a trial.
  • Safety and effects beyond a week for GHRP-6 alone.
  • Whether the stroke result in people with severe strokes holds up in a trial designed to test it.
  • How GHRP-6 compares with GHRP-2, hexarelin or ipamorelin in people.
  • What is in the vials sold online, and whether the form matches the studies.

Retracted and flagged studies

A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.

We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention GHRP-6. We recheck every month. Last checked Nov 12, 2026.

We found no retracted, withdrawn or flagged studies that mention GHRP-6.

Studies this page relies on

Status of every study cited on this page
Study Published in Status
Hartman et al., 1992 J Clin Endocrinol Metab No retraction or concern
Bellone et al., 1995 Eur J Endocrinol No retraction or concern
Frieboes et al., 1995 Neuroendocrinology No retraction or concern
Ghigo et al., 1994 Eur J Endocrinol No retraction or concern
Pandya et al., 1998 J Clin Endocrinol Metab No retraction or concern
Frieboes et al., 1999 J Neuroendocrinol No retraction or concern
Popovic et al., 2000 Lancet No retraction or concern
Frieboes et al., 2004 Psychoneuroendocrinology No retraction or concern
Laferrère et al., 2005 J Clin Endocrinol Metab No retraction or concern
Cibrián et al., 2006 Clin Sci (Lond) No retraction or concern
Berlanga et al., 2007 Clin Sci (Lond) No retraction or concern
Alaioubi et al., 2009 Horm Metab Res No retraction or concern
Alaioubi et al., 2010 Horm Metab Res No retraction or concern
Cabrales et al., 2013 Eur J Pharm Sci No retraction or concern
Subirós et al., 2016 Neurol Res No retraction or concern
Berlanga-Acosta et al., 2017 Clin Med Insights Cardiol No retraction or concern
Krug et al., 2018 Growth Horm IGF Res No retraction or concern
Zhang et al., 2023 Peptides No retraction or concern
Dominikowski et al., 2026 Front Endocrinol (Lausanne) No retraction or concern
Hernández-Bernal et al., 2026 J Clin Neurosci No retraction or concern

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

What is GHRP-6?

A lab-made peptide of six amino acids that copies the signal of ghrelin and makes the pituitary release growth hormone. It is not approved anywhere we found (Berlanga-Acosta et al., 2017).

Is GHRP-6 a peptide?

Yes. It has six amino acids, two of them in the mirror-image D form (Cabrales et al., 2013).

What does GHRP-6 do to you?

A single intravenous dose raised growth hormone sharply, and it raised cortisol and ACTH (Hartman et al., 1992; Frieboes et al., 1995).

Does GHRP-6 make you hungry?

It is widely said to, but we found no trial of GHRP-6 that measured it. A related peptide, GHRP-2, raised meal intake by 35.9% in 7 men (Laferrère et al., 2005).

Does GHRP-6 increase muscle mass?

Not shown. IGF-1 did not rise significantly after 4 days of oral dosing in older women, and a 2026 review calls the evidence limited (Ghigo et al., 1994; Dominikowski et al., 2026).

What are the side effects of GHRP-6?

Higher cortisol and ACTH in studies, and more severe adverse events in the stroke trial, though none were judged treatment-related (Frieboes et al., 1995; Hernández-Bernal et al., 2026).

Is GHRP-6 safe?

We don’t know long term. The studies were short, and the FDA lists concerns about cortisol, blood sugar and immune reactions (FDA, 2026).

GHRP-6 vs GHRP-2: which is better?

No human trial compared them. GHRP-2 has the food-intake study (Laferrère et al., 2005), and GHRP-6 has the sleep and diagnostic studies above.

Is hexarelin the same as GHRP-6?

No, but it was derived from it. See hexarelin; in sleep studies, hexarelin cut deep sleep and GHRP-6 did not (Frieboes et al., 2004; Frieboes et al., 1995).

Does GHRP-6 work by mouth?

At 300 micrograms per kilogram it matched an injection of 1 microgram per kilogram, but lower oral doses did not beat placebo (Hartman et al., 1992).

Is GHRP-6 FDA approved, and is it legal?

It is not approved. Drugs@FDA lists no product, and no trial is registered under the name (openFDA search, no match; ClinicalTrials.gov search). Our guide to what to look for covers the routes people use.

Is GHRP-6 banned in sports?

Yes. The World Anti-Doping Agency lists GHRP-6 as prohibited at all times (WADA, 2026).

Is GHRP-6 used in medicine?

As a diagnostic test: given with GHRH, it separated 125 adults with growth hormone deficiency from 125 healthy adults (Popovic et al., 2000).

What is the GHRP-6 half-life?

About 2.5 hours in a study of intravenous doses of 100 to 400 micrograms per kilogram in nine men (Cabrales et al., 2013).

What is the GHRP-6 dosage?

Studies gave 1 microgram per kilogram intravenously for diagnostic tests, 30 to 300 micrograms per kilogram by mouth, 300 micrograms per kilogram by mouth twice a day for 4 days, 30 micrograms per kilogram as a nasal spray, and four 50 microgram intravenous doses overnight (Popovic et al., 2000; Hartman et al., 1992; Ghigo et al., 1994; Frieboes et al., 1999; Frieboes et al., 1995). The stroke trial gave 5 mg by vein twice a day for 7 days with EGF (Hernández-Bernal et al., 2026). No study has set a dose for use outside a trial, and we don’t give dosing advice.

Is GHRP-6 the same as D-Lys3-GHRP-6?

No. [D-Lys3]-GHRP-6 blocks the ghrelin receptor and is a research tool (Zhang et al., 2023).

Sources

  1. Hartman ML, et al. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab. 1992;74(6):1378-84. PubMed 1592884
  2. Pandya N, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-9. PubMed 9543138
  3. Cabrales A, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-6. PubMed 23099431
  4. Bellone J, et al. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. 1995;133(4):425-9. PubMed 7581965
  5. Ghigo E, et al. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol. 1994;131(5):499-503. PubMed 7952160
  6. Frieboes RM, et al. Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. 1999;11(6):473-8. PubMed 10336729
  7. Frieboes RM, et al. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. 1995;61(5):584-9. PubMed 7617137
  8. Popovic V, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137-42. PubMed 11030292
  9. Alaioubi B, et al. Diagnosis of growth hormone deficiency in adults: provocative testing with GHRP6 in comparison to the insulin tolerance test. Horm Metab Res. 2009;41(3):238-43. PubMed 19006049
  10. Alaioubi B, et al. Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. Horm Metab Res. 2010;42(3):198-203. PubMed 19946832
  11. Laferrère B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-4. PubMed 15699539
  12. Hernández-Bernal F, et al. Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke. J Clin Neurosci. 2026;152:112195. PubMed 42462342
  13. Berlanga-Acosta J, et al. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. PubMed 28469491
  14. Berlanga J, et al. Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond). 2007;112(4):241-50. PubMed 16989643
  15. Cibrián D, et al. Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond). 2006;110(5):563-73. PubMed 16417467
  16. Subirós N, et al. Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy. Neurol Res. 2016;38(3):187-95. PubMed 26311576
  17. Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. PubMed 29864719
  18. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
  19. Frieboes RM, et al. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology. 2004;29(7):851-60. PubMed 15177700
  20. Zhang H, et al. Inhibition of ghrelin activity by the receptor antagonist [D-Lys3]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model. Peptides. 2023;166:171041. PubMed 37301480
  21. ClinicalTrials.gov. Searches for GHRP-6, GHRP6 and growth hormone releasing peptide 6, November 12, 2026: no studies. Search
  22. U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 12, 2026: no GHRP-6 product or label. openFDA search, no match
  23. U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
  24. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
  25. World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. WADA document
  26. Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
  27. U.S. Food and Drug Administration. Global Substance Registration System: HEXAPEPTIDE-2 (UNII 4H7N4I6X6A). GSRS
  28. U.S. Food and Drug Administration. Global Substance Registration System: HEXAPEPTIDE-2 ACETATE (UNII USP2MY0E7I). GSRS

Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.